A Pilot Study of the Effect of NM-504 Cobiotic Formulation on the Efficacy and Tolerability of Metformin in Patients With Metformin Intolerance

Trial Profile

A Pilot Study of the Effect of NM-504 Cobiotic Formulation on the Efficacy and Tolerability of Metformin in Patients With Metformin Intolerance

Completed
Phase of Trial: Phase 0

Latest Information Update: 08 Aug 2014

At a glance

  • Drugs NM 504 (Primary) ; Metformin
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Acronyms ProCo-Metformin
  • Sponsors MicroBiome Therapeutics
  • Most Recent Events

    • 23 Jul 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 16 Dec 2013 MicroBiome Therapeutics completed bridge financing intended to support completion of this trial, according to a company media release.
    • 22 Sep 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top